适应性生物科技的CennoSEQ测试显示,通过测量残余疾病,对血癌治疗进行量身定做很有希望。 Adaptive Biotechnologies' clonoSEQ test shows promise in tailoring blood cancer treatments by measuring residual disease.
适应性生物技术在ASH会议上提供了新的数据,表明它们的ClinoSEQ测试能够准确测量血癌中的残余疾病,帮助定制治疗。 Adaptive Biotechnologies presented new data at the ASH meeting showing that their clonoSEQ test can accurately measure residual disease in blood cancers, helping tailor treatments. 研究表明,残留疾病水平低的患者有更好的结果,建议测试可以指导决策,避免不必要的治疗,如干细胞移植。 Studies revealed that patients with low levels of residual disease had better outcomes, suggesting the test can guide decisions to avoid unnecessary treatments like stem cell transplants. 研究结果可能导致更个性化和更有效的癌症护理。 The findings could lead to more personalized and effective cancer care.